Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.790
-0.040 (-1.04%)
Nov 3, 2026, 3:09 PM EST - Market open

Recursion Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-475.67-644.76-463.66-328.07-239.48-186.48
Depreciation & Amortization
73.8583.736.4924.411.768.41
Loss (Gain) From Sale of Assets
-4.5----
Asset Writedown & Restructuring Costs
-28.040.111.192.81-
Stock-Based Compensation
88.5111.2281.6953.527.9114.84
Other Operating Activities
22.6831.832.965.458.564.92
Change in Accounts Receivable
-6.2732.94-6.07-7.76-0-5.38
Change in Accounts Payable
2.79-2.626.44-0.991.771.75
Change in Unearned Revenue
-21.36-36.77-28.04-41.08110.32-10
Change in Other Net Operating Assets
4.9520.14-19.085.56-7.1613.33
Operating Cash Flow
-310.53-371.81-359.17-287.78-83.52-158.61
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1.95-6.47-13.7-11.96-37.06-39.8
Cash Acquisitions
--277.11.84--
Divestitures
--4.44----
Sale (Purchase) of Intangibles
-2-2.16-3.35-0.6-0.3-
Investment in Securities
--3.81-0.48230.61-231.95
Investing Cash Flow
-3.95-16.87260.06-10.23193.25-271.74

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
--8.43-4.44-0.77-0.09-12.8
Net Debt Issued (Repaid)
-8.92-8.43-4.44-0.77-0.09-12.8
Issuance of Common Stock
219.69532.96308.56140.9154.44471.34
Other Financing Activities
-0.36-3----
Financing Cash Flow
210.41521.53304.12140.13154.35458.54

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-1.5518.04-3.410.19-0.31-
Net Cash Flow
-105.62150.9201.6-157.69263.7628.18

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-312.48-378.28-372.87-299.74-120.58-198.41
Free Cash Flow Growth
------
Free Cash Flow Margin
-457.97%-506.52%-633.71%-672.43%-302.64%-1949.42%
Free Cash Flow Per Share
-0.59-0.84-1.36-1.44-0.69-1.58
Levered Free Cash Flow
-266.61-208.52-194.33-187.37-105.41-121.93
Unlevered Free Cash Flow
-266.61-207.39-193.35-187.31-105.37-120.09

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
-----0.68
Change in Working Capital
-19.8913.69-46.76-44.26104.92-0.31
SEC Filings: 10-K · 10-Q